Deep Sequencing Detects V3 loop Forms Present in Functional X4 Viruses Growing in MT 2 assays

Similar documents
Multicenter comparison of genotypic tropism testing: results from viral RNA and proviral DNA

HIV-1 envelope glycoproteins isolated from Viremic non-progressors HIV-infected individuals are fully functional and cytophatic

Disclosure. Relations that could be relevant for the meeting

DETECTION OF LOW FREQUENCY CXCR4-USING HIV-1 WITH ULTRA-DEEP PYROSEQUENCING. John Archer. Faculty of Life Sciences University of Manchester

Laboratory Testing for HIV Tropism

HIGH VIRAL LOAD AND TREATMENT RESPONSE

geno2pheno[ngs-freq]: a novel tool for drug resistance testing in the era of nextgeneration

Original Policy Date

Supplemental Materials and Methods Plasmids and viruses Quantitative Reverse Transcription PCR Generation of molecular standard for quantitative PCR

Improvement of Quality of Life after the Application of Mindfulness-Based Cognitive Therapy in Subjects Aging with HIV Infection

JCM (Revised version, June 23 th 2011)

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

Medical Policy Laboratory Testing for HIV Tropism Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory. Description.

Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo

Deep-Sequencing of HIV-1

Clinical application of ultradeep sequencing in the management of HIV infection

Alexander Thielen 16th European Meeting on HIV & Hepatitis

Laboratory Testing for HIV Tropism. Description

Laboratory Testing for HIV Tropism

Stability of unfrozen whole blood DNA for remote genotypic analysis of HIV-1 coreceptor tropism

Clinical Case. Prof.ssa Cristina Mussini

HIV-1 resistance testing from proviral DNA

Treatment of HIV and acute myeloid leukemia by allogeneic CCR5-d32 blood stem cell transplantation. Elena Knops

Journal of Infectious Diseases Advance Access published April 18, Using Ultradeep Pyrosequencing to Study HIV 1 Co receptor Usage in Primary and

Laboratory Testing for HIV Tropism

Innovative diagnostics for HIV, HBV and HCV

Caring for HIV infected patients in Spain during the current economical crisis

Switching strategies and ARV treatment costs

Identification of a cytokine expression pattern specific for the first month of HIV infection


GSS resistant intermediate resistant susceptible NRTI - NtRTI NNRTI etravirine PI PI/r EI INI dolutegravir

Virological failure to Protease inhibitors in Monotherapy is linked to the presence of signature mutations in Gag without changes in HIV-1 replication

HIV-1 Dual Infection and Neurocognitive Impairment

An Analysis of Genital Tract Derived HIV from Heterosexual Transmission Pairs. Debrah Boeras Emory University October 14, 2008

Inves&gación básica y curación del VIH-1

Program. Wednesday, 30 May

Distribution of CD31 on CD4 T-Cells from Cord Blood, Peripheral Blood and Tonsil at Different Stages of Differentiation

Analysis of HIV-1 Resistance Mutations from various Compartments of the Peripheral Blood in Patients with Low-Level Viremia

Supplementary Figure 1. ALVAC-protein vaccines and macaque immunization. (A) Maximum likelihood

SUPPLEMENTARY FIG. S1. MVC inhibition curves in NP2-CD4/CCR5 cells. Luciferase reporter viruses pseudotyped with baseline (black solid lines) and MVC

Single genome analysis reveals genetic characteristics of Neuroadaptation across HIV-1 envelope

DNA Genotyping in HIV Infection

Alternate Antibody-Based Therapeutic Strategies To Purge the HIV Cell Reservoir

Supplementary Figure 1. Gating strategy and quantification of integrated HIV DNA in sorted CD4 + T-cell subsets.

European guidelines on the clinical management of HIV-1 tropism testing

Eradication of HIV Bonaventura Clotet Hospital Universitàri Germans Trias i Pujol Badalona. Barcelona. Catalonia

Received 4 August 2005/Accepted 7 December 2005

HIV-1 co-receptor tropism in recently diagnosed patients: correlates of CXCR4-use, impact of subtype and indications for X4/DM virus transmission

New technologies reaching the clinic

Inves)gación básica y curación del VIH- 1

Diversity and Tropism of HIV-1 Plasma Rebound Virus after Treatment Discontinuation

Bonaventura Clotet. HIV Unit & Retroviroloy Lab Univ Hosp Germans Trias i Pujol Badalona, Catalonia, Spain

Update on HIV-1 Drug Resistance and Tropism Testing

Low-Level Viremia in HIV

Ongoing HIV Replication During ART Reconsidered

Reconstructing the Dynamics of HIV Evolution within Hosts from Serial Deep Sequence Data

Improving PI drug resistance scores. Jens Verheyen, MD Institute of Virology University Duisburg-Essen

Blood biomarkers for the early diagnosis of dementia with Lewy bodies

Models of HIV during antiretroviral treatment

PRO140 SC Monotherapy (MT) Provides Long-Term, Full Virologic Suppression in HIV Patients

Chronic HIV-1 Infection Frequently Fails to Protect against Superinfection

Removal of dolutegravir by hemodialysis in HIV-infected patients with end-stage. renal disease

HIV-1 Subtypes: An Overview. Anna Maria Geretti Royal Free Hospital

Prevention of infection 2 : immunisation. How infection influences the host : viruses. Peter

Added Value of Deep Sequencing Relative to Population Sequencing in Heavily Pre-Treated HIV-1-Infected Subjects

MEETING PROSPECTUS 3 RD EUROPEAN WORKSHOP ON WORKSHOP ON HEALTHY LIVING WITH HIV.

A Double-Blind, Placebo-Controlled Trial of Maraviroc in Treatment-Experienced Patients Infected with Non-R5 HIV-1

Professor Jonathan Weber

HIV/AIDS & Immune Evasion Strategies. The Year First Encounter: Dr. Michael Gottleib. Micro 320: Infectious Disease & Defense

Sustained HIV- 1 remission following homozygous CCR5 delta- 32 allogeneic haemopoetic stem cell transplantion

Antiretroviral Prophylaxis and HIV Drug Resistance. John Mellors University of Pittsburgh

Downloaded from:

COMPARISON OF HIV DRUG-RESISTANT MUTANT DETECTION BY NGS WITH AND WITHOUT UNIQUE MOLECULAR IDENTIFIERS (UMI)

Supplementary Figure 1

JOURNAL OF VIROLOGY, July 1999, p Vol. 73, No. 7. Copyright 1999, American Society for Microbiology. All Rights Reserved.

Changes in cellular HIV DNA levels during the MONET trial: 144 Weeks of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs

MedChem 401~ Retroviridae. Retroviridae

Recent Insights into HIV Pathogenesis and Treatment: Towards a Cure

Host-Specific Modulation of the Selective Constraints Driving Human Immunodeficiency Virus Type 1 env Gene Evolution

Resistance Workshop. 3rd European HIV Drug

1300 CID 2010:50 (1 May) HIV/AIDS. Received 24 November 2009; accepted 20 January 2010; electronically published 30 March a

Science Supporting Online Material

Variation of Human Immunodeficiency Virus Type-1 Reverse Transcriptase within the Simian Immunodeficiency Virus Genome of RT-SHIV

Circumcision and penile human papillomavirus prevalence in human immunodeficiency virus-infected men: heterosexual and men who have sex with men

HIV-1 acute infection: evidence for selection?

Abstract. Editor: M. Paul

Monotherapy with boosted PIs as an ART simplification strategy in clinical practice

Whole-Genome Characterization of Human and Simian Immunodeficiency Virus Intrahost Diversity by Ultradeep Pyrosequencing

Novel Viral Markers Predict HIV Disease Progression

CROI 2016: Top Ten for Clinicians

Micropathology Ltd. University of Warwick Science Park, Venture Centre, Sir William Lyons Road, Coventry CV4 7EZ

Isolation of a Broadly Neutralizing Antibody with Low Somatic Mutation from a Chronically Infected HIV-1 Patient

Characterization and data assessment of NGS-based genotyping using VQA HIVDR proficiency panels

Citation for published version (APA): Von Eije, K. J. (2009). RNAi based gene therapy for HIV-1, from bench to bedside

Roger Shapiro, MD, MPH Harvard TH Chan School of Public Health Botswana-Harvard Partnership May 2018

YUMI YAMAGUCHI-KABATA AND TAKASHI GOJOBORI* Center for Information Biology, National Institute of Genetics, Mishima , Japan

SUPPLEMENTARY INFORMATION. Divergent TLR7/9 signaling and type I interferon production distinguish

Establishment and Targeting of the Viral Reservoir in Rhesus Monkeys

activity REPORt 2013

Transcription:

Deep Sequencing Detects V3 loop Forms Present in Functional X4 Viruses Growing in MT 2 assays Christian Pou 1, Rocío Bellido 1, Francisco M. Codoñer 1, Alexander Thielen 3, Cecilia Cabrera 1, Judith Dalmau 1, Martin Däumer 4, Bonaventura Clotet 1,2, Roger Paredes 1,2 and the Barcelona Tropism Study Group. 1 Institut de Recerca de la SIDA irsicaixa HIVACAT & 2 HIV Unit Fundació Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Catalonia, Spain; 3 Max Planck Institut für Informatik, Saarbücken, Germany; 4 Institut für Immunologie und Genetik, Kaiserslautern, Germany.

BACKGROUND HIV Tropism testing is mandatory before treatment with CCR5 antagonists. Deep V3 loop sequencing (454 Life Sciences/Roche) Achieves similar diagnostic accuracy to ESTA in plasma Can be performed in proviral DNA in subjects with undetectable VL Proviral DNA could act as a repository of non functional viruses stored along infection. Does 454 detect functional viruses? We investigated if V3 loop forms of X4 viruses growing in MT2 assays were also detected by deep sequencing in plasma and/or proviral DNA.

METHODS Study design and participants Retrospective proof of concept study Inclusion criteria: Chronically HIV 1 infected adults with HIV 1 RNA <50 copies/ml during at least 2 years after starting first line ART without CCR5 antagonists. Subjects had to have cryopreserved samples available for testing: Within 6 months before ART initiation (T1). After at least 2 years of undetectable viremia (T2). ART without CCR5 antagonists Viral Load <50 copies/ml 96 weeks QDS: Plasma ARN Proviral DNA MT2 assay QDS: Proviral DNA MT2 assay

METHODS Assays and Internal Controls MT2 assay Patient derived PBMCs + MT2 cell line Syncytium formation and p24 production (ELISA) Virus extraction from supernatant and sequencing by Sanger Parallel control to asses virus growth ability Patient derived PBMCs + PBMC from healthy seronegative donors Quantitative Deep Sequencing HXB2 genome 1st round PCR 2nd round PCR X4: Geno2Pheno FPR=10% Parallel control to assess error induced during polymerization events Sequencing of commercial pnl4.3 DNA clone

RESULTS Per subject and timepoint determination of viral load, CD4+ cells count and tropism prediction Phylogenetic analysis Filtering of sequences achieved by QDS (Error established at 0.6) Population sequences from MT2 V3 Alignment with HAMMER Test of the best nucleotide evolutionary model using FindModel Construction of Maximum likelihood trees using PhyML Edition of trees using MEGA

RESULTS Comparison between V3 loop sequences from MT2 stocks and QDS before ART administration. Subject 1 Subject 3 Subject 4 Subject 5 64 65 60 66 81 69 51 63 80 85 61 57 Subject 2 55 87 71 99 98 99 51 67 55 69 68 Empty R5 / Filled X4 QDS Plasma ARN QDS Proviral DNA MT2 59 76 54

RESULTS Comparison between V3 loop sequences from MT2 stocks and QDS during viremia suppression Subject 1 Subject 3 Subject 4 100 80 55 54 72 92 80 100 96 96 63 88 96 99 100 77 Empty R5 / Filled X4 QDS Proviral DNA T2 MT2

CONCLUSIONS At least one of the predominant V3 forms with predicted CXCR4 use detected by deep sequencing in plasma or PBMCs is shared by functional X4 viruses growing in MT 2 assays. This suggests that deep sequencing detects functional X4 viruses with the potential to escape from CCR5 antagonist selective pressure, adding clinical value to the technology.

CAVEATS This does not mean that all X4 viruses detected by 454 are functional. V3 is the main determinant of co receptor specificity, but tropism also depends on the env background where this V3 form exists.

ACKNOWLEDGMENTS Institut de Recerca de la SIDA IrsiCaixa (Badalona) Rocío Bellido Francisco Codoñer Cecília Cabrera Judith Dalmau Mattia Schiaulini Marc Noguera Maria Casadellà Cristina Rodríguez Roger Paredes Bonaventura Clotet Max-Planck-Institut für Informatik (Saarbücken) Alexander Thielen Institut für Immunologie und Genetik (Kaiserslautern) Martin Däumer Pfizer, CHAIN